Joseph Giaimo, DO
Pulmonary Disease · Palm Beach Gardens, FLNPI 1083615736
Payments from drug & device makers
Across 199 payments — averaging $97.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$13K
- Intuitive Surgical$3K
- GSK$763
- Inogen, Inc.$743
- AstraZeneca$352
- Insmed, Inc.$189
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$12,17063%
- Travel & lodging$8004%
- Food & beverage$3,78019%
- Education$2,63314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 31 | $13,028 |
| Intuitive Surgical | 5 | $3,225 |
| GSK | 60 | $763 |
| Inogen, Inc. | 35 | $743 |
| AstraZeneca | 19 | $352 |
| Insmed, Inc. | 10 | $189 |
| Verona Pharma, Inc. | 5 | $140 |
| Fisher & Paykel Healthcare Inc | 4 | $136 |
| Cook Medical LLC | 1 | $135 |
| Actelion Pharmaceuticals US, Inc. | 3 | $95 |
| Inspire Medical Systems, Inc. | 3 | $81 |
| Sanofi | 3 | $81 |
| Baxter Healthcare | 4 | $73 |
| Amgen | 3 | $67 |
| Caris MPI, Inc. | 2 | $57 |
| Lilly USA, LLC | 3 | $51 |
| Philips North America LLC | 1 | $33 |
| Pulmonx Corporation | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Resmed Corp | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Merck | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,178
- Zilver PTX$135
How this compares
$19,383 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 429 | $393,872 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 87 | $76,180 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 92 | $56,398 |
| Spiriva RespimatTiotropium Bromide | 66 | $48,053 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $42,614 |
| SymbicortBudesonide/Formoterol Fumarate | 94 | $29,850 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $21,783 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 167 | $8,500 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $8,006 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $6,785 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,222 |
| Ventolin HfaAlbuterol Sulfate | 34 | $3,598 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $2,986 |
| Doxycycline Hyclate | 44 | $426 |
| Prednisone | 87 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $763 | $472,053559 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $13,028 | $124,233153 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $352 | $80,471142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Palm Beach Gardens
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.